Free Trial

Zevra Therapeutics (ZVRA) Competitors

Zevra Therapeutics logo
$12.34 +0.78 (+6.75%)
As of 11:12 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ZVRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMY

Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

Zevra Therapeutics vs. Its Competitors

Vericel (NASDAQ:VCEL) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Vericel has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

In the previous week, Zevra Therapeutics had 11 more articles in the media than Vericel. MarketBeat recorded 13 mentions for Zevra Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.73 indicating that Vericel is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vericel
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

35.0% of Zevra Therapeutics shares are held by institutional investors. 5.2% of Vericel shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vericel has a net margin of 1.25% compared to Zevra Therapeutics' net margin of -226.78%. Vericel's return on equity of 1.09% beat Zevra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vericel1.25% 1.09% 0.73%
Zevra Therapeutics -226.78%-201.05%-53.55%

Vericel has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$237.22M9.01$10.36M$0.031,415.33
Zevra Therapeutics$23.61M28.58-$105.51M-$1.90-6.49

Vericel currently has a consensus target price of $61.14, indicating a potential upside of 44.00%. Zevra Therapeutics has a consensus target price of $23.71, indicating a potential upside of 92.17%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Vericel beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVRA vs. The Competition

MetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$674.20M$2.43B$5.59B$9.00B
Dividend YieldN/A1.80%5.25%4.03%
P/E Ratio-6.499.3627.5420.18
Price / Sales28.58603.19415.83171.78
Price / CashN/A161.3437.0657.97
Price / Book16.684.658.105.61
Net Income-$105.51M$31.26M$3.17B$248.59M
7 Day Performance26.11%6.39%3.33%4.67%
1 Month Performance32.97%3.65%3.54%7.18%
1 Year Performance119.57%2.23%33.62%21.21%

Zevra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVRA
Zevra Therapeutics
2.7637 of 5 stars
$12.34
+6.7%
$23.71
+92.2%
+111.1%$674.20M$23.61M-6.4920News Coverage
Analyst Forecast
VCEL
Vericel
2.9526 of 5 stars
$41.79
+0.8%
$61.14
+46.3%
-9.9%$2.10B$237.22M1,393.30300
AGIO
Agios Pharmaceuticals
4.0801 of 5 stars
$36.06
+2.0%
$58.60
+62.5%
-8.5%$2.09B$36.50M3.21390
CGON
CG Oncology
2.3802 of 5 stars
$26.90
+0.8%
$58.67
+118.1%
-15.8%$2.05B$1.14M-17.8161
KNSA
Kiniksa Pharmaceuticals International
3.4517 of 5 stars
$27.86
+1.5%
$38.80
+39.3%
+42.4%$2.03B$423.24M-111.42220Analyst Forecast
BEAM
Beam Therapeutics
2.6711 of 5 stars
$20.02
+0.7%
$48.75
+143.5%
-10.0%$2.01B$63.52M0.00510Gap Up
IDYA
IDEAYA Biosciences
3.428 of 5 stars
$22.09
+0.8%
$53.42
+141.8%
-40.5%$1.94B$7M-6.1580News Coverage
Analyst Upgrade
IRON
Disc Medicine
3.1744 of 5 stars
$54.75
+3.0%
$96.70
+76.6%
+18.9%$1.90BN/A0.0030Insider Trade
BLTE
Belite Bio
2.6536 of 5 stars
$59.74
+5.2%
$96.67
+61.8%
+30.4%$1.89BN/A0.0010News Coverage
Analyst Revision
CNTA
Centessa Pharmaceuticals
2.5912 of 5 stars
$14.34
+4.3%
$27.89
+94.6%
+43.3%$1.88B$6.85M0.00200
HRMY
Harmony Biosciences
4.8222 of 5 stars
$32.09
-0.1%
$53.63
+67.1%
-0.8%$1.85B$714.73M12.27200Positive News

Related Companies and Tools


This page (NASDAQ:ZVRA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners